NASDAQ:IMAB - Nasdaq - US44975P1030 - ADR - Currency: USD
NASDAQ:IMAB (5/23/2025, 8:25:08 PM)
0.99
-0.06 (-5.71%)
The current stock price of IMAB is 0.99 USD. In the past month the price increased by 17.94%. In the past year, price decreased by -43.43%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.84 | 323.71B | ||
AMGN | AMGEN INC | 13.09 | 146.07B | ||
GILD | GILEAD SCIENCES INC | 13.87 | 133.56B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.96B | ||
REGN | REGENERON PHARMACEUTICALS | 13.28 | 63.52B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.81B | ||
ARGX | ARGENX SE - ADR | 100.1 | 35.88B | ||
ONC | BEIGENE LTD-ADR | 6.17 | 26.10B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.72B | ||
NTRA | NATERA INC | N/A | 20.94B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.20B | ||
BIIB | BIOGEN INC | 7.95 | 18.43B |
I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company is headquartered in Rockville, Maryland and currently employs 32 full-time employees. The company went IPO on 2020-01-17. The firm is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.
I-MAB-SPONSORED ADR
Suite 400, 2440 Research Blvd
Rockville MARYLAND 201210 US
CEO: Joan Huaqiong Shen
Employees: 32
Phone: 13016702800
The current stock price of IMAB is 0.99 USD. The price decreased by -5.71% in the last trading session.
The exchange symbol of I-MAB-SPONSORED ADR is IMAB and it is listed on the Nasdaq exchange.
IMAB stock is listed on the Nasdaq exchange.
9 analysts have analysed IMAB and the average price target is 5.61 USD. This implies a price increase of 466.67% is expected in the next year compared to the current price of 0.99. Check the I-MAB-SPONSORED ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
I-MAB-SPONSORED ADR (IMAB) has a market capitalization of 80.07M USD. This makes IMAB a Micro Cap stock.
I-MAB-SPONSORED ADR (IMAB) currently has 32 employees.
I-MAB-SPONSORED ADR (IMAB) has a support level at 0.89 and a resistance level at 1.06. Check the full technical report for a detailed analysis of IMAB support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
IMAB does not pay a dividend.
I-MAB-SPONSORED ADR (IMAB) will report earnings on 2025-08-26.
I-MAB-SPONSORED ADR (IMAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.82).
The outstanding short interest for I-MAB-SPONSORED ADR (IMAB) is 1.06% of its float. Check the ownership tab for more information on the IMAB short interest.
ChartMill assigns a technical rating of 6 / 10 to IMAB. When comparing the yearly performance of all stocks, IMAB is a bad performer in the overall market: 80.64% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to IMAB. IMAB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months IMAB reported a non-GAAP Earnings per Share(EPS) of -0.82. The EPS increased by 89.81% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -10.33% | ||
ROE | -10.95% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 82% to IMAB. The Buy consensus is the average rating of analysts ratings from 9 analysts.